12:00 AM
May 06, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Cimzia certolizumab pegol regulatory update

UCB disclosed in its 1Q13 earnings that FDA and EMA accepted for review regulatory applications to extend the label for Cimzia certolizumab pegol to include treatment of active psoriatic arthritis and active...

Read the full 137 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >